These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34229037)

  • 1. Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis.
    Narula N; Wong ECL; Colombel JF; Riddell R; Marshall JK; Reinisch W; Dulai PS
    Clin Gastroenterol Hepatol; 2022 May; 20(5):1095-1104.e9. PubMed ID: 34229037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Histological and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared with Endoscopic Improvement Alone in Ulcerative Colitis: A Post hoc Analysis of the VARSITY study.
    Wong ECL; Dulai PS; Hasan B; Marshall JK; Reinisch W; Narula N
    J Crohns Colitis; 2023 Jul; 17(7):1114-1121. PubMed ID: 36821429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
    Li K; Marano C; Zhang H; Yang F; Sandborn WJ; Sands BE; Feagan BG; Rubin DT; Peyrin-Biroulet L; Friedman JR; De Hertogh G
    Gastroenterology; 2020 Dec; 159(6):2052-2064. PubMed ID: 32853634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis.
    Parkes G; Ungaro RC; Danese S; Abreu MT; Arenson E; Zhou W; Ilo D; Laroux FS; Deng H; Sanchez Gonzalez Y; Peyrin-Biroulet L
    J Gastroenterol; 2023 Oct; 58(10):990-1002. PubMed ID: 37490069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
    Peyrin-Biroulet L; Loftus EV; Colombel JF; Danese S; Rogers R; Bornstein JD; Chen J; Schreiber S; Sands BE; Lirio RA
    Gastroenterology; 2021 Oct; 161(4):1156-1167.e3. PubMed ID: 34144047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Inflamm Bowel Dis; 2024 Mar; 30(3):370-381. PubMed ID: 37116893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials.
    Li K; Strauss R; Marano C; Greenbaum LE; Friedman JR; Peyrin-Biroulet L; Brodmerkel C; De Hertogh G
    J Crohns Colitis; 2019 Aug; 13(8):1025-1035. PubMed ID: 30721964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis.
    Wong ECL; Hasan B; Dulai PS; Marshall JK; Reinisch W; Narula N
    Scand J Gastroenterol; 2023 Jan; 58(1):7-14. PubMed ID: 35909369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
    Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study.
    Narula N; Wong ECL; Marshall JK; Jairath V; Dulai PS; Reinisch W
    Am J Gastroenterol; 2023 Jan; 118(1):121-128. PubMed ID: 36066459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histologic Evaluation Using the Robarts Histopathology Index in Patients With Ulcerative Colitis in Deep Remission and the Association of Histologic Remission With Risk of Relapse.
    Park J; Kang SJ; Yoon H; Park J; Oh HJ; Na HY; Lee HS; Shin CM; Park YS; Kim N; Lee DH
    Inflamm Bowel Dis; 2022 Nov; 28(11):1709-1716. PubMed ID: 35016209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil-only Histological Assessment of Ulcerative Colitis Correlates with Endoscopic Activity and Predicts Long-term Outcomes in a Multicentre Study.
    Parigi TL; Cannatelli R; Nardone OM; Zammarchi I; Shivaji U; Furfaro F; Zardo D; Spaggiari P; Del Sordo R; Setti O; Majumder S; Smith SCL; Danese S; Armuzzi A; Villanacci V; Ghosh S; Iacucci M
    J Crohns Colitis; 2023 Dec; 17(12):1931-1938. PubMed ID: 37390319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Intestinal Ultrasound Predicts Long-Term Endoscopic Response to Biologics in Ulcerative Colitis.
    Allocca M; Dell'Avalle C; Furfaro F; Zilli A; D'Amico F; Peyrin-Biroulet L; Fiorino G; Danese S
    J Crohns Colitis; 2023 Nov; 17(10):1579-1586. PubMed ID: 37084137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing.
    Jangi S; Yoon H; Dulai PS; Valasek M; Boland BS; Jairath V; Feagan BG; Sandborn WJ; Singh S
    Aliment Pharmacol Ther; 2020 Sep; 52(6):1008-1016. PubMed ID: 33119168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of histological activity in predicting endoscopic relapse among patients of ulcerative colitis in endoscopic remission].
    Liu M; Yao Y; Ye JX; Li J; Shi XY
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):709-715. PubMed ID: 38955703
    [No Abstract]   [Full Text] [Related]  

  • 17. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
    Turner D; Griffiths AM; Veerman G; Johanns J; Damaraju L; Blank M; Hyams J
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1460-5. PubMed ID: 23672831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological healing after infliximab induction therapy in children with ulcerative colitis.
    Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
    World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis.
    Nardone OM; Bazarova A; Bhandari P; Cannatelli R; Daperno M; Ferraz J; Goetz M; Gui X; Hayee B; De Hertogh G; Lazarev M; Li J; Parra-Blanco A; Pastorelli L; Panaccione R; Occhipinti V; Rath T; Smith SCL; Shivaji UN; Tontini GE; Vieth M; Villanacci V; Zardo D; Bisschops R; Kiesslich R; Ghosh S; Iacucci M
    United European Gastroenterol J; 2022 Mar; 10(2):147-159. PubMed ID: 35194978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis.
    Pai RK; Hartman DJ; Rivers CR; Regueiro M; Schwartz M; Binion DG; Pai RK
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2510-2517.e5. PubMed ID: 31843598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.